GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE
2024年8月5日 - 10:00PM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical technology company focused on the design, development, and
commercialization of novel technologies for people with diabetes,
today announced that an emerging science industry poster will be
presented at the Association of Diabetes Care and Education
Specialists (ADCES) 2024 Annual Conference to be held August 9-12,
2024 in New Orleans, LA.
The Glucotrack poster will present market
research data on the acceptance of the Company’s Continuous Blood
Glucose Monitor (CBGM) concept among people with type 1 and type 2
diabetes.
“We look forward to sharing our findings on our
continuous blood glucose monitor with the diabetes care community
at ADCES,” said Paul V. Goode, PhD, CEO of Glucotrack. “This data
contributes to the growing body of evidence demonstrating the need
for and growing interest in expanding glucose monitoring
options.”
The poster will be made available on the
Glucotrack website following the poster session at the conference.
Presentation details are as follows; times noted are Eastern
time:
Poster Title: Evaluating
Acceptance of a Continuous Blood Glucose Monitor for
Insulin-Requiring People with DiabetesPoster Session Date /
Time: Saturday, August 10, 12:15 PM - 1:15 PM
For more information about Glucotrack’s CBGM,
visit glucotrack.com.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on
the design, development, and commercialization of novel
technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose
monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable
system that continually measures blood glucose levels with a sensor
longevity of 2+ years, no on-body wearable component and with
minimal calibration. For more information, please
visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “believe”, “expect”, “plan” and “will” are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, management. These statements relate only to events as of the
date on which the statements are made, and Glucotrack undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements
made in this press release are qualified by these cautionary
statements, and there can be no assurance that the actual results
anticipated by Glucotrack will be realized or, even if
substantially realized, that they will have the expected
consequences to or effects on us or our business or operations.
Readers are cautioned that certain important factors may affect
Glucotrack’s actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect Glucotrack’s results
include, but are not limited to, the ability of Glucotrack to raise
additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and
timing) of regulatory approvals (including U.S. Food and Drug
Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to
Glucotrack’s future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2023 as filed with the SEC on March
28, 2024.
Contacts:
Investor Relations:investors@glucotrack.com
Media:GlucotrackPR@icrinc.com
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 8 2024 まで 9 2024
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 9 2023 まで 9 2024